Financial Performance - Enlight Renewable Energy Ltd. reported significant growth in revenue, with a year-over-year increase of 25% to $150 million[15] - Enlight projects a revenue growth of 20% for the next fiscal year, targeting $180 million[15] - The company achieved a total installed capacity of 1.5 GW, representing a 30% increase compared to the previous year[15] - User data indicates a 40% increase in customer base, reaching 500,000 users[15] Investment and Development - The company is investing $50 million in new technology development to enhance energy efficiency[15] - The company plans to launch two new renewable energy products in Q3 2024, expected to contribute an additional $30 million in revenue[15] - Enlight is exploring strategic acquisitions to bolster its portfolio, with a budget of $100 million allocated for potential mergers[15] - Market expansion efforts include entering three new states, aiming for a 15% market share in those regions by 2025[15] Operational Efficiency and Challenges - Enlight's operational efficiency improved, with a reduction in costs by 10% due to optimized supply chain management[15] - The company experienced project delays ranging from 6 to 24 months in 2025 due to regulatory reforms and extended reviews by regulators[65] - The company reported that several projects faced challenges in obtaining interconnection rights, which could significantly impact revenue and operational capacity[65] - The company is facing increased interconnection costs and longer approval times, which complicate project planning and could adversely affect the development pipeline[70] Regulatory and Compliance Risks - The company emphasizes its commitment to ESG standards, aligning with evolving regulatory requirements and stakeholder interests[15] - The company must navigate legal, regulatory, and compliance risks across multiple jurisdictions, which could affect operations and profitability[26] - The Uyghur Forced Labor Prevention Act may impact the supply chain, particularly concerning components sourced from the Xinjiang region of China, potentially leading to delays or increased costs[76] - The company must secure various governmental and environmental approvals, which are becoming more demanding and may delay project timelines[72] Market and Competitive Landscape - The company is subject to risks related to intense competition from traditional utilities and renewable energy companies in project development[25] - Competition in the renewable energy sector is intensifying, with traditional energy companies posing a threat to securing favorable offtake contracts[88] - Intense competition for offtake contracts may lead to downward pressure on pricing, adversely affecting revenue and financial performance[90] Financial Risks - The company is exposed to electricity price volatility, which could affect cash flows under certain offtake arrangements[25] - The company relies on a limited number of operational projects for a substantial portion of its cash flows, increasing financial risk[26] - The company is exposed to credit risk from offtakers, which could impact cash flows and financing for future projects if counterparties default[96] - The company may incur significant liquidated damages and penalties if it fails to complete renewable energy projects in accordance with contractual obligations[65] Environmental and Operational Risks - The company is subject to risks associated with the performance of solar and wind energy projects, including potential degradation of equipment and increased operational costs[102] - The company highlighted that electricity prices are volatile, influenced by factors such as new lower-cost generation plants and changes in demand, which could negatively impact financial results[114] - The company experienced operational disruptions and repair costs due to quality failures in turbine blades and other equipment, which may not be fully compensated under warranty agreements[108] - The company reported that severe weather and natural catastrophes could significantly reduce energy output, leading to decreased total revenues and increased operational costs[106] Cybersecurity and Data Management - The company experienced one cyber-related incident in 2024, classified as immaterial, causing no damage to its data or infrastructure[142] - Cybersecurity risks are expected to increase, with a growing number of intrusion attempts blocked by the company's defensive measures[142] - The company is subject to risks associated with litigation or administrative proceedings that could materially affect its operations and financial condition[138] Supply Chain and Material Costs - The company is subject to risks from fluctuating market prices of raw materials such as steel, aluminum, copper, and lithium, which could increase project costs[74] - The company's supply chain policy aims to mitigate the impact of tariffs by sourcing equipment from countries unaffected by trade restrictions[178] - Future tariffs could increase the price of solar systems in the U.S., potentially reducing demand and affecting gross margins[179] Debt and Financing - As of December 31, 2025, the company's consolidated indebtedness was approximately $4.8 billion, net of deferred financing costs[201] - The company had approximately $1.7 billion of consolidated variable-rate debt outstanding and $3.1 billion of fixed-rate debt outstanding as of December 31, 2025[198] - The company expects to rely heavily on third-party project financing, including tax equity arrangements, which may not be available in the future[205] - The cost of tax equity financing has increased and may continue to do so, potentially limiting the company's ability to develop and acquire additional assets[206]

Capital and Financing - Fermi America raised approximately $1.8 billion in capital since inception, with $935 million capitalized into property, plant, and equipment by December 31, 2025[6]. - The initial public offering (IPO) on October 1, 2025, raised $785 million at $21 per share, priced at the top of the range due to oversubscription[25]. - Year-to-date cash provided by financing activities was $1.0 billion, with significant contributions from the IPO ($745.6 million) and the issuance of Preferred Units ($107.6 million)[62]. Infrastructure Development - The company has contracted, financed, and delivered a multi-gigawatt generation pipeline, with power equipment on site, in transit, or in fabrication across three continents[17]. - Fermi's first six Siemens Energy SGT-800 turbines, rated at 478 MW, have arrived and are part of a broader strategy to deliver power at scale[21]. - The company has completed 11.3 miles of perimeter fencing and 4.6 miles of gas pipeline, with infrastructure capable of supporting approximately 2 GW of generation[41]. - Fermi has secured a grid connection agreement expected to deliver 86 MW upon initial energization, ramping to 1,000 MW[23]. Regulatory and Permitting - Fermi secured a Clean Air Permit for approximately 6 GW of natural gas generation, one of the largest permits ever issued for a private power project in the U.S.[30]. - The company has received a 6 GW clean air permit and plans to file for an additional 5 GW of capacity, with expectations to execute binding tenant agreements and begin vertical construction within the next twelve months[57][58]. - Fermi's nuclear program has progressed to the Nuclear Regulatory Commission (NRC) review stage, with a Combined Operating License Application filed for four Westinghouse AP1000 reactors[35]. Financial Performance - The company reported a year-to-date net loss of $486.4 million, primarily due to $441.8 million in non-cash charges, including a $173.8 million charitable contribution and $132.7 million in share-based compensation[59]. - Cash used in operating activities was $34.2 million, while cash used in investing activities totaled $570.3 million, mainly for early-stage development of Project Matador[60][61]. - Fermi holds approximately $1.4 billion in total assets, including $935.3 million in property, plant, and equipment, and $408.5 million in cash and cash equivalents as of December 31, 2025[64][65]. Market Position and Strategy - Eight covering analysts rate Fermi a Buy or Strong Buy, with an average price target of $29, indicating that the current share price does not reflect the company's built value[52]. - The commercial pipeline has expanded significantly, with active discussions with multiple prospective tenants, including hyperscale cloud operators and AI infrastructure companies[50]. - Fermi aims to secure a creditworthy anchor tenant to support project financing structures, which is crucial for unlocking non-recourse project debt and de-risking equity[51]. - The company is committed to long-term ownership and alignment with shareholders, with significant shareholders involved in the management team[56].

Financial Performance - Reviva reported a net loss of approximately $19.9 million, or $5.48 per share, for the fiscal year ended December 31, 2025, a decrease from a net loss of approximately $29.9 million, or $17.73 per share, for the fiscal year ended December 31, 2024[9][17]. - Total operating expenses for 2025 were $20.2 million, down from $30.8 million in 2024, with research and development expenses at $11.7 million compared to $22.9 million in the previous year[9][17]. - Reviva's total assets as of December 31, 2025, were approximately $15.9 million, compared to $15.5 million as of December 31, 2024[9][15]. Cash Position - As of December 31, 2025, the company's cash and cash equivalents totaled approximately $14.4 million, an increase from approximately $13.5 million as of December 31, 2024[9][15]. - The company has cash and cash equivalents of approximately $23 million following the March 2026 offering, which is expected to fund operations into Q1-2027[9][9]. Clinical Development - The company plans to initiate the RECOVER-2 registrational Phase 3 trial for brilaroxazine in mid-2026, with trial-related activities starting in Q2-2026 and patient enrollment in the U.S. expected to begin in Q3-2026[9][8]. - Brilaroxazine demonstrated robust efficacy in a one-year study, with a PANSS total score improvement of -18.1 and only <1% of patients reporting symptom relapse[9][6]. - The Phase 3 RECOVER trial data package includes a well-tolerated safety profile observed in over 900 subjects treated to date[9][6]. Funding Activities - The company completed public equity offerings in June 2025, September 2025, and March 2026, raising gross proceeds of $10.0 million, $9.0 million, and $10.0 million, respectively[9][9]. Intellectual Property - Reviva's patent portfolio includes a European Patent granted in November 2025 for the use of brilaroxazine in treating pulmonary fibrosis, expanding its protection in key markets[9][9].

Financial Performance - In Q4 2025, Sigma Lithium generated cash from operations of US$31 million, with cash inflows of US$41 million and operating costs of US$10 million[4]. - Sigma Lithium achieved net sales revenues of approximately US$67 million in Q4 2025 and Q1 2026, with sales of about 650,000 tonnes of high-purity lithium fines and approximately 5,000 tonnes of high-grade premium lithium oxide concentrate[9]. - The operating cash margin was 47% in Q4 2025, with a 77% year-over-year decline in operating costs offsetting a 64% drop in net sales revenues[10]. - Cash inflows for Q1 2026 were US$35 million, with cash and equivalents as of March 30, 2026, totaling US$12 million[5]. - The company reduced trade finance debt by 60% and total debt by 35% in 2025, with total debt at year-end 2025 standing at US$141 million[11]. Production and Sales Agreements - The company signed two offtake agreements totaling US$146 million, including US$96 million for 70,500 tonnes in 2026 and US$50 million for 40,000 tonnes per year for three years starting in 2026[6][8]. - Sigma Lithium expects to produce 240,000 tonnes of high-grade premium lithium oxide concentrate in the next twelve months at an all-in sustaining cost of US$592 per tonne[12]. - The company plans to continue its successful commercial strategy, benefiting from the flexibility in the timing of product delivery under the signed agreements[8]. Environmental Sustainability - Sigma Lithium's Greentech Industrial Plant emphasizes environmental sustainability, utilizing 100% renewable electricity and zero toxic chemicals[15]. - The company is undergoing a Phase 2 expansion to nearly double its production capacity to 520,000 tonnes annually[16].

Financial Performance - The loss for Kazia Therapeutics Limited for the half-year ended 31 December 2025 was $12,552,490, compared to a loss of $10,453,811 for the same period in 2024, representing an increase of approximately 20%[4] - The total comprehensive loss for the half-year was $13,412,383, compared to $10,279,476 in the previous year, reflecting an increase of approximately 30%[29] - Kazia Therapeutics reported a loss after income tax of $12,552,490 for the half-year ended December 31, 2025, compared to a loss of $10,453,811 for the same period in 2024, representing an increase of approximately 20%[38] - The basic loss per share for December 2025 was (0.805) cents, a decrease from (2.459) cents in December 2024[77] Cash and Funding - Total cash resources at 31 December 2025 amounted to $69,459,980, a significant increase from $4,344,691 at 30 June 2025[6][30] - The company raised $46.51 million through a PIPE transaction on 2 December 2025, contributing to the current cash balance[9] - The company raised $65,248,181 through the issuance of shares during the half-year, significantly up from $16,387,602 in the previous half-year[32] - Cash and cash equivalents at the end of the financial half-year stood at $69,459,980, a substantial increase from $4,344,691 at the beginning of the period[32] - The net proceeds from the December 2025 PIPE were US$46.51 million after deducting offering expenses, with 4,530,854,000 ordinary shares sold at a price of $0.01 per share[54] - The company raised total proceeds of US$1,397,016 using the ATM facility from July to December 2025, with a remaining capacity of US$35.19 million[61] Research and Development - Research and development expenses for the half-year were $4,992,238, up from $4,282,101 in the previous year, indicating a year-over-year increase of approximately 17%[29] - Kazia Therapeutics expanded its clinical development of paxalisib into multiple breast cancer settings, including a Phase 1b study in metastatic triple-negative breast cancer[10] - The company reported an 86% reduction in overall tumor burden in a case treated with a combination immunotherapy/chemotherapy regimen plus paxalisib[13] Compliance and Governance - The company regained compliance with Nasdaq listing standards on 18 December 2025, ensuring continued trading of its ADSs[9] - The company continued to comply with Nasdaq listing requirements, regaining compliance with the minimum market value of listed securities[39] - The directors are responsible for preparing the half-year financial report in accordance with Australian Accounting Standards and the Corporations Act 2001[85] - The financial report must give a true and fair view of the Group's financial position as of December 31, 2025, and its performance for the half-year ended on that date[87] - The auditor's responsibility includes expressing a conclusion on the half-year financial report based on a review, not an audit, which is less comprehensive[89] Assets and Liabilities - The net current asset position improved to $45,612,689 as of 31 December 2025, compared to a net current liability of $9,119,727 at 30 June 2025[7] - The company had a net current asset position of $45,612,689 as of December 31, 2025, a significant improvement from a net current liability of $9,119,727 as of June 30, 2025[38] - Trade payables increased to $6,127,338 from $5,644,797, reflecting higher operational liabilities[49] - Employee benefits provisions increased to US$445,975 in December 2025 from US$426,786 in June 2025[57] - The foreign currency translation reserve showed a negative balance of US$1,633,404 in December 2025, compared to a negative balance of US$773,511 in June 2025[73] - The share-based payments reserve increased to US$6,737,860 in December 2025 from US$3,873,198 in June 2025[73] - The deferred tax liability associated with the licensing agreement remained unchanged at US$271,629 from June 2025 to December 2025[58] Employee Compensation - Kazia Therapeutics' employee share-based payment expense increased to $4,634,705 for the half-year, compared to $290,053 in the previous year[42] - The company incurred transaction costs of A$5,278,293 related to the PIPE, allocated between equity and derivative liability components[54]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K I.R.S. Employer Identification No. 4514 Cole Avenue, Suite 1600 Dallas, Texas 75204 Address of Principal Executive Offices Zip Code ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _______________ Commission f ...

Company Structure and Operations - The company is a blank check company with no operating history and no revenues, which may hinder the evaluation of its ability to achieve business objectives [162]. - The company is a special purpose acquisition company with no business operations prior to completing a business combination [357]. - The company is classified as an "emerging growth company" and may take advantage of exemptions from certain disclosure requirements, which could affect the attractiveness of its securities to investors [321]. - The company is also a "smaller reporting company," allowing it to provide only two years of audited financial statements, which may complicate comparisons with other public companies [323]. - The company has not opted out of the extended transition period for new financial accounting standards, which may lead to difficulties in comparing its financial statements with those of other public companies [322]. - The company is incorporated under the laws of the Cayman Islands, which may limit investors' ability to protect their interests and enforce judgments obtained in U.S. courts [327]. - The company maintains its executive offices in Dallas, Texas, with a monthly fee of $10,000 for office space and administrative services [358]. - There is no material litigation or governmental proceedings currently pending against the company or its management team [359]. Shareholder Rights and Voting - Public shareholders may not have the opportunity to vote on the proposed initial business combination, potentially allowing completion even without majority support [164]. - The sponsor owns 20% of the issued and outstanding ordinary shares, which may influence shareholder votes on business combinations [166]. - The company requires 8,694,000 public shares, or 36% of the 24,150,000 public shares sold, to be voted in favor of an initial business combination for approval [166]. - The absence of a specified maximum redemption threshold may allow the company to complete a business combination even if a majority of shareholders disagree [204]. - The company may seek shareholder approval to extend the deadline for the initial business combination, allowing Class A ordinary shareholders to redeem their shares at a price based on the trust account balance [182]. - The company may not hold an annual meeting of shareholders until after the initial business combination is consummated, limiting shareholder engagement [201]. Financial Condition and Risks - The total funds in trust available for the initial business combination amount to $241,500,000, with 24,150,000 public shares included in public units [174]. - If the initial business combination is not completed within 24 months, public shareholders may receive only approximately $10.00 per share or less upon liquidation [181]. - The potential for dilution increases if public shareholders exercise redemption rights, which could lead to a greater number of shares being redeemed than initially expected [176]. - The company may face significant competition for business combination opportunities due to limited resources [163]. - The company may face challenges in completing a business combination due to market conditions and geopolitical risks, including conflicts in Ukraine and the Middle East [180]. - The company may not complete its initial business combination within the required time period, potentially forcing liquidation and resulting in public shareholders receiving an estimated $10.00 per share or less [197]. - The trust account funds may be vulnerable to third-party claims, potentially reducing the per-share redemption amount below $10.00 [210]. - If claims against the company arise, the amount available for public shareholders could be diminished, affecting the per-share value [212]. - The company may not be able to complete its initial business combination if trust account funds are reduced below $10.00 per share due to third-party claims [221]. - The company may need to seek additional financing to complete its initial business combination, and failure to secure such financing could compel it to abandon the proposed transaction [266]. - The trust account funds may bear a negative interest rate, potentially reducing the per-share redemption amount for public shareholders to less than $10.00 [267]. Business Combination Challenges - The company may face challenges in identifying suitable targets due to the increasing number of special purpose acquisition companies in the market [192]. - The company may seek business combination opportunities with large, complex companies that require significant operational improvements, which could delay achieving desired results [198]. - The company may face challenges in completing its initial business combination with multiple target businesses due to complex accounting issues and the need for pro forma financial statements, which could limit diversification and increase economic and regulatory risks [237]. - If the company attempts to acquire several businesses simultaneously, it may encounter increased costs and risks, including difficulties in negotiations and due diligence, which could negatively impact profitability [238]. - The company may pursue business combinations with targets outside the U.S., exposing it to significant income and withholding tax obligations in multiple jurisdictions [337]. Regulatory and Compliance Issues - The company may be subject to extensive government regulations that could increase operational costs and impact financial performance [225]. - The SEC's guidance on SPACs indicates that a SPAC's status as an investment company depends on various factors, and non-compliance could lead to liquidation and loss of investment opportunities for shareholders [253]. - The company must ensure that its activities do not classify it as an investment company under the Investment Company Act, which would impose burdensome compliance requirements [249]. - The company faces challenges in complying with laws and regulations, which could adversely affect its business operations and ability to complete its initial business combination [320]. - The company may face heightened scrutiny and restrictions on foreign investments due to evolving national security regulations in the U.S. and other countries [245]. Conflicts of Interest - The company may face conflicts of interest as executive officers and directors are not required to commit full time to its affairs, potentially impacting the ability to complete the initial business combination [286]. - Executive officers and directors have fiduciary obligations to other entities, which may limit their ability to devote time to the company's affairs and affect the completion of the initial business combination [288]. - The company may engage in business combinations with target businesses affiliated with its sponsor or directors, raising potential conflicts of interest that may not favor public shareholders [293]. - Key personnel may negotiate employment agreements that could create conflicts of interest during the business combination process [284]. - The personal and financial interests of executive officers and directors may influence their motivation in selecting a target business, potentially leading to conflicts of interest [292]. Shareholder Indemnification and Warrants - The company may not have sufficient funds to satisfy indemnification claims for its sponsor and directors, which could discourage shareholder lawsuits [296]. - The company has the ability to amend the terms of public warrants with the approval of at least 50% of the outstanding warrants, potentially affecting holders adversely [297]. - The company may redeem unexpired warrants at a price of $0.01 per warrant if certain conditions are met, which could disadvantage warrant holders [298]. - The company may require holders to exercise their public warrants on a cashless basis, resulting in fewer Class A ordinary shares received compared to cash exercise [299]. - The potential issuance of a substantial number of additional Class A ordinary shares upon exercise of these warrants could make the company a less attractive acquisition vehicle [301]. Market Conditions and Economic Factors - The ongoing military conflict between Russia and Ukraine may disrupt market conditions and adversely affect the company's search for a business combination [259]. - Macro-economic instability, including high unemployment and rising interest rates, could negatively impact the company's financial condition and its ability to locate a viable target for business combination [261]. - Recent inflation increases could lead to price volatility for publicly traded securities, complicating the completion of the initial business combination [280]. Miscellaneous - The company has not identified any significant cybersecurity risks that materially affect its business strategy and results of operations [357]. - The company may incur additional costs if the forum provisions of its warrant agreement are found inapplicable or unenforceable [326]. - The company may not make cash distributions to shareholders for tax liabilities arising from business combinations, requiring shareholders to cover these costs from personal funds [339].

Clinical Development - AIM ImmunoTech is focusing its efforts on developing Ampligen for late-stage pancreatic cancer, which presents a significant market opportunity due to over 450,000 deaths worldwide in 2022[13] - The ongoing Phase 2 clinical trial (DURIPANC study) is evaluating Ampligen in combination with AstraZeneca's Imfinzi for metastatic pancreatic cancer, with 18 patients enrolled so far[14] - The company has established a partnership with Thermo Fisher Scientific to design a Phase 3 clinical trial for Ampligen in late-stage pancreatic cancer[15] - AIM is exploring Ampligen's potential as a treatment for post-COVID conditions, with a Phase 2 study involving 80 subjects completed in February 2024[21] - The company is also investigating Ampligen's use as a vaccine adjuvant in combination with AstraZeneca's FluMist for enhanced immune response against avian influenza[20] - Ampligen has shown promising results in pre-clinical studies for various viral infections, including COVID-19, with significant impacts on viral replication observed[19] - Ongoing clinical trials include the DURIPANC study, which combines Ampligen with AstraZeneca's Imfinzi for late-stage pancreatic cancer, showing promising results with 21% of subjects achieving progression-free survival over 6 months[68] - The Phase 2 AMP-270 clinical trial aims to compare Ampligen with standard care in advanced pancreatic adenocarcinoma, with approximately 90 subjects expected to enroll across 30 centers[70] - A Phase 2 study of Ampligen in advanced recurrent ovarian cancer reported an Objective Response Rate of 45% in platinum-sensitive subjects, with a median Progression-Free Survival of 7.8 months[73] - The Phase 1 study for early-stage triple negative breast cancer showed a primary endpoint of safety and tolerability was met, with 5 out of 9 patients (56%) achieving a pathologic complete response (pCR)[76] - In the Phase 2 study for refractory melanoma, patient enrollment was temporarily suspended but resumed; however, the study was ultimately terminated with only 1 patient enrolled[77] - The Phase 1/2a trial for metastatic or unresectable triple negative breast cancer was terminated with 5 patients enrolled, indicating challenges in recruitment and funding[78] - A total of 42 pancreatic cancer patients received Ampligen treatment under the Expanded Access Program (EAP), with over 50 patients ultimately treated[81] - The median overall survival for patients treated with Ampligen in a named patient program was 19 months, significantly higher than historical controls (7.5 and 12.5 months)[88] - Ampligen demonstrated antiviral activity against SARS-CoV-2, suggesting potential as a treatment or prophylaxis against COVID-19[92] - The Phase 1/2a study of Ampligen and interferon alpha in cancer patients with COVID-19 plans to enroll up to 44 patients, with initial results reported by Roswell Park[95] - Ampligen demonstrated a 90% reduction in SARS-CoV-2 infectious viral yields at clinically achievable intranasal dosage levels in research conducted at Utah State University[96] - The AMP-511 Expanded Access Program for ME/CFS was expanded to include Long-COVID patients, with eight patients treated since January 2021[97] - A Phase 1 study of Ampligen showed no serious adverse events among 40 healthy subjects, supporting its potential as a prophylaxis or treatment for COVID-19[98] - Two provisional patent applications for Ampligen related to Post-COVID conditions were filed, with early data indicating improvements in fatigue symptoms[99] - The Phase 2 study AMP-518 enrolled 80 subjects, with topline data expected to show significant improvements in fatigue-related measures[102] Financial Position - AIM has reported a working capital deficit and stockholders' equity below the minimum requirement for continued listing on the NYSE American, raising concerns about its ability to continue as a going concern[27] - As of December 31, 2025, the stockholders' deficit was approximately ($9,783,000), necessitating an increase in stockholders' equity to at least $6,000,000 to regain compliance with listing standards[28] - A reverse stock split was authorized on a one-for-100 basis to help regain compliance with the NYSE American listing requirements[29] - The company has a history of losses and expects to continue incurring losses in the near term, raising substantial doubt about its ability to continue as a going concern[38] - The company may seek to raise additional funds, which could dilute existing ownership and negatively impact stock price[38] - The accumulated deficit was approximately $440,786,000 as of December 31, 2025, highlighting ongoing financial challenges and uncertainty regarding future profitability[159] - The company does not generate any material revenue from operations and does not anticipate doing so in the near future, necessitating further funding for product development[157] - The company has approximately $3,047,000 in cash, cash equivalents, and marketable securities, indicating a need for additional financing[157] - The company is currently not in compliance with the Exchange continued listing requirements, which could lead to delisting of its securities[38] - The company is not currently in compliance with the Exchange's listing requirements and has submitted a plan to regain compliance by June 11, 2026[141] - If the common stock is delisted, it may be subject to "penny stock" rules, which could limit trading activity and liquidity[144] - The company may face significant dilution of ownership if it raises additional funds through the issuance of equity securities[145] - The trading price of the common stock may be highly volatile and subject to wide fluctuations due to various factors beyond the company's control[150] - The company is classified as a "smaller reporting company," which may make its common stock less attractive to investors due to reduced disclosure requirements[155] - If the company is unable to obtain necessary regulatory approvals in a timely manner, its operations and stock price may be adversely affected[164] - The approval of Ampligen by the FDA remains uncertain, with potential delays and additional studies required that could extend the timeline for commercialization[170] Regulatory and Compliance - Ampligen received Orphan Drug Designation from the FDA for pancreatic cancer, providing seven years of market exclusivity upon approval[86] - The FDA granted clearance to proceed with a Phase 2 study for locally advanced pancreatic cancer after a previous clinical hold was lifted[85] - The FDA issued a Complete Response Letter for the NDA of Ampligen in February 2013, indicating that the submitted data did not provide substantial evidence of efficacy for the treatment of CFS[163] - Regulatory approval for Ampligen in Argentina has been received, but additional steps are required before commercial sales can commence[162] - The company has received Orphan Drug Designation from the FDA for Ampligen in treating multiple conditions, including Chronic Fatigue Syndrome and Ebola Virus Disease, which qualifies for various incentives[64] - The company has received approval from ANMAT for the commercial sale of Ampligen in Argentina for the treatment of severe CFS, with marketing to be conducted by GP Pharm (now Filaxis)[207] - The next steps for the commercial launch of Ampligen include a final inspection and release tests by ANMAT, which are currently delayed due to internal processes[208] Manufacturing and Production - The company has completed production of over 16,000 vials of Ampligen for multiple programs, including ME/CFS and pancreatic cancer treatment[57] - The validation of the polymer production process with Sterling Pharma Solutions is ongoing, necessary for future Ampligen manufacturing[58] - The production of new Alferon N Injection Active Pharmaceutical Ingredient is currently on hold, with no timeline for commercial availability[61] - The manufacturing process for Alferon N Injection is on hold, and there is no definitive timetable for its restart, which could materially affect operations[196] - The company is exploring engaging a Contract Manufacturing Organization (CMO) to produce Alferon active pharmaceutical ingredients (API) due to halted commercial sales from lack of finished goods inventory[196] - The company has limited manufacturing experience for Ampligen and Alferon N Injection, and profitability is contingent on producing these products in commercial quantities at acceptable costs[204] - There are limited suppliers available for raw and packaging materials necessary for the production of Ampligen and Alferon N Injection, which poses a risk to manufacturing capabilities[193] Market and Competition - The worldwide market for injectable alpha interferon-based products has seen rapid growth, with various products approved for major medical uses globally[60] - Alferon N Injection is the only natural-source, multi-species alpha interferon approved for sale in the U.S. and Argentina, specifically for treating refractory external genital warts in patients aged 18 and older[59] - Alferon N Injection has a low side-effect profile and no neutralizing antibodies observed to date, contrasting with recombinant formulations that may lose effectiveness after one year due to antibody formation[61] - The company faces significant competition from major pharmaceutical companies like Pfizer and Merck, which have greater financial resources and capabilities[132] - The company is pursuing licensing and collaboration strategies to make Ampligen available globally, targeting partners with strong commercial infrastructure and experience in relevant therapeutic areas[122] - The commercialization strategy for Ampligen may involve licensing or co-marketing agreements with strategic partners, with the goal of establishing a relationship before FDA approval[210] Risks and Challenges - The company has limited product liability and clinical trial insurance coverage, which may expose it to significant financial risks from product liability claims[166] - There is significant uncertainty regarding health care reimbursement for Ampligen and Alferon N Injection, which could impact the company's ability to realize returns on product development investments[167] - Ampligen's development is subject to risks including potential ineffectiveness, adverse side effects, and challenges in obtaining necessary regulatory approvals[175] - The company has not yet secured patents for Ampligen as a sole treatment for targeted cancers, which could hinder its marketability[185] - The patent landscape for biotechnology and pharmaceutical firms is complex and uncertain, with potential litigation that could drain resources[187] - The company has received various designations, including Orphan Drug Product Designation and "promising" clinical outcome recognition based on clinical reports[48] - The loss of key personnel could adversely affect the company's operations and ability to achieve its objectives[171] - The company has limited marketing and sales capabilities, relying on third-party distributors to generate significant revenues and achieve profitability[209]

Financial Performance - The company reported a net loss of $64,829 for the period from September 12, 2025, to December 31, 2025, due to formation and administrative costs[312]. - The company does not expect to generate operating revenues until after the completion of its initial business combination[311]. Initial Public Offering (IPO) - The company completed its Initial Public Offering on January 29, 2026, raising gross proceeds of $230,000,000 from the sale of 23,000,000 units, including 3,000,000 units from the over-allotment option[314]. - Transaction costs related to the Initial Public Offering amounted to $12,602,226, including $4,600,000 in cash underwriting fees and $8,050,000 in deferred underwriting fees[317]. - The underwriters exercised their over-allotment option fully, purchasing an additional 3,000,000 units at the IPO price[324]. - An additional $6,450,000 was raised from the sale of 645,000 private placement units at a price of $10.00 per unit[315]. Use of Proceeds - The company placed $230,000,000 from the IPO proceeds into a trust account, to be invested in U.S. government treasury obligations or money market funds until a business combination is completed[316]. - The company does not anticipate needing to raise additional funds post-IPO to meet operational expenditures[319]. Financial Obligations - The company had an outstanding balance of $143,875 on a promissory note from the sponsor, which was repaid upon the IPO completion[323]. - As of December 31, 2025, the company had no off-balance sheet arrangements[321].

IPO and Financial Proceeds - The company completed its Initial Public Offering (IPO) on March 24, 2025, raising gross proceeds of $143,750,000 from the sale of 14,375,000 Public Units at $10.00 each[23]. - An additional $5,656,250 was generated from the private sale of 565,625 Private Placement Units, bringing total proceeds to $144,181,250, which is held in a Trust Account[24][25]. - The company incurred $8,409,601 in Initial Public Offering related costs, which included a cash underwriting fee of $2,875,000 and a Deferred Fee of $5,031,250[177]. - The Underwriters were paid a cash underwriting discount of $2,875,000, which is 2.0% of the gross proceeds from the Initial Public Offering[189]. - The Deferred Fee payable to the Underwriters upon completion of the initial Business Combination amounts to $5,031,250[189]. - As of December 31, 2025, the company had cash of $1,093,209 held outside the Trust Account for operational activities[182]. - The company has approximately $1,093,209 in proceeds held outside the Trust Account as of December 31, 2025, which may be used for dissolution costs if necessary[109]. Business Combination Strategy - The company is focused on pursuing Business Combination opportunities primarily in Israel, particularly in sectors such as mobility, electric vehicles, autonomy, robotics, agricultural technologies, and financial technology[22][32]. - The company aims to identify target businesses with competitive advantages and disruptive technologies to ensure attractive returns for investors[33]. - The management team has a history of successful transactions, including a previous SPAC that completed a Business Combination with Freightos Limited, valued at $390,000,000[35]. - The company anticipates structuring the initial Business Combination to acquire 100% of the equity interests or assets of the target business[52]. - The company must complete one or more Business Combinations with an aggregate fair market value of at least 80% of the assets held in the Trust Account[51]. - The company may seek to extend the Combination Period with shareholder approval, which could affect its Nasdaq listing[27]. - The company may engage finders to identify potential Business Combination opportunities, with fees typically tied to the completion of a transaction[63]. - The company may pursue Business Combinations with affiliated companies, provided an independent valuation opinion is obtained[64]. Shareholder Rights and Redemption - The company will provide Public Shareholders the opportunity to redeem shares upon completion of the initial Business Combination, regardless of their voting stance[85]. - Public Shareholders must deliver share certificates or electronically transfer Public Shares to exercise redemption rights, with specific deadlines outlined in proxy materials[101]. - If the initial Business Combination is not approved, Public Shareholders who elected to redeem will not receive their pro rata share of the Trust Account[104]. - The company requires Public Shareholders to redeem their Public Shares through specified methods, applicable regardless of registration status under the Exchange Act or Nasdaq listing[89]. - If shareholder approval is sought, Public Shareholders can redeem up to 15% of Public Shares sold in the Initial Public Offering without prior consent, which aims to prevent large block accumulations[99]. - The redemption price for Public Shares as of December 31, 2025, was approximately $10.35 per share, calculated based on the aggregate amount in the Trust Account[85]. - The company may not complete the initial Business Combination if the cash required for redemptions exceeds available cash, and all submitted Public Shares will be returned[98]. - Upon failure to complete the initial Business Combination, the company will redeem Public Shares at a per-share price based on the Trust Account balance, subject to certain conditions[106]. Management and Governance - The management team and board consist of experienced industry leaders, enhancing the company's ability to identify suitable acquisition targets[36]. - The company is classified as an "emerging growth company" and can take advantage of certain exemptions from reporting requirements[123]. - The company will remain an emerging growth company until it has total annual gross revenue of at least $1.235 billion or the market value of its Class A Ordinary Shares exceeds $700 million[125]. - The company is also a "smaller reporting company," allowing it to provide only two years of audited financial statements[126]. - The company is classified as a "controlled company" under Nasdaq corporate governance standards, as more than 50% of the voting power is held by a specific group[127]. - The company has no operating history or revenues, which limits shareholders' ability to evaluate its business objectives[128]. - The company’s disclosure controls and procedures were deemed effective as of December 31, 2025[200]. Risks and Challenges - The company faces competition from other SPACs, private equity groups, and public companies, which may limit its ability to acquire larger target businesses[117]. - The company may face increased competition for attractive Business Combination targets, potentially raising costs and complicating the completion of such combinations[128]. - Recent fluctuations in inflation and interest rates could hinder the ability to consummate an initial Business Combination[129]. - The company may be deemed a passive foreign investment company, which could result in adverse U.S. federal income tax consequences for its U.S. shareholders[143]. - The company is subject to various risks related to regulatory approvals and compliance, particularly if the target is located outside the United States[136]. - The company may experience significant dilution for Public Shareholders due to the nominal purchase price of Founder Shares, which was approximately $0.005 per share[139]. - The company’s Public Shareholders may face limited rights regarding funds in the Trust Account, potentially forcing them to sell shares at a loss[139]. - The company may face challenges in enforcing shareholder rights due to its incorporation in the Cayman Islands, potentially complicating legal recourse[139]. - The company has not yet secured third-party financing, which may affect its ability to complete the initial Business Combination[57]. - Management has determined that the company currently lacks the liquidity to sustain operations for at least one year, raising substantial doubt about its ability to continue as a going concern[186]. - The company faces risks related to conflicts in Ukraine and the Middle East, which could materially affect its ability to find a target business for its initial Business Combination[144]. - Ongoing geopolitical tensions may lead to market disruptions, including volatility in commodity prices and capital markets, impacting the company's operations[145]. Financial Performance - For the year ended December 31, 2025, the company reported a net income of $3,473,428, primarily from interest earned on marketable securities held in the Trust Account[176]. - As of December 31, 2025, the company had marketable securities in the Trust Account totaling $148,724,491, including $4,543,241 of interest income[180]. - The company has not generated any operating revenues to date and will not do so until after the completion of its initial Business Combination[175]. - The company has no long-term debt or capital lease obligations as of December 31, 2025[187]. - The company has not made any borrowings under Working Capital Loans as of December 31, 2025[185]. - The company has the potential to convert up to $1,500,000 of Working Capital Loans into units at a price of $10.00 per unit[185]. - The company has not paid any cash dividends on its Ordinary Shares and does not intend to do so prior to the completion of its initial Business Combination[160].